A new infliximab biosimilar coming from India

October 15, 2012 8:14 AM

A new infliximab biosimilar from Reliance Life Sciences, India is at the clinical phase, The Indian Express reports.

According to the report, a course of four injections of the originator drug, Remicade costs Rs 2-3 lakh and the new biosimilar will lower the costs by 50 percent. The new biosimilar has been manufactured and will be tested in a multi-centric clinical trial among 189 rheumatoid arthritis patients across India.

Dr Arvind Chopra, Director at Centre for Rheumatic Diseases, and one of the investigators of the clinical trial in Pune told The Indian Express that with the patents of biologic drugs beginning to expire in the next two-three years, several manufacturers have geared up for the next big — biosimilars — as they promise a potential for more affordable therapy.

In the June issue of Indian Journal of Rheumatology, Chopra has focused on how biologic disease modifying anti-rheumatic drugs (DMARD) have revolutionised the management of several rheumatic disorders, especially those with autoimmune inflammatory disorders. The prevalence of clinical RA recently reported by the WHO ILAR COPCORD (community oriented program for control of rheumatic diseases) urban and rural surveys in India varied from 0.45 to 0.68%. This translates into more than 10 million of RA patients with an aggressive crippling disease, Chopra pointed out.

When contacted, Dr K Mahendranath, former president of Indian Rheumatology Association, told The Indian Express from Bangalore that access to biologics has been restricted due to its exorbitant cost.

Treatment with biologic drugs like infliximab, etanercept and others are extremely expensive (cost ranges from Rs 70,000 for drugs per month to Rs 5 lakh for four injections).

The trial has been approved by Drug Controller General of India (DCGI). The trial will get under way at several trial sites, including New Delhi, Pune, Hyderabad, Bangalore, Chennai.

Dr L Duggal, Head of the department of rheumatology at Sir Gangaram Hospital, New Delhi, and among the clinical trial investigators, when contacted, said it was an important clinical trial and if it works, prices of the medicine for treating RA can be considerably reduced.

Source: The Indian Express

 

2 Comments

  • mayank pathak

    Where to get Remicade at a cheap price as the cost is really high.
    What to do to live with the pain or get it from the right source at affordable price.

  • Hi,
    Anyone knows if this medicine is available in India right now and how much it costs? I am in US and I am taking remicade dosage. I can’t afford it in india.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!